Jon Cuthbert - Author on Grafa
All
Palvella Therapeutics outlines robust 2026 roadmap for QTORIN platform
Palvella Therapeutics (NASDAQ:PVLA) issued a comprehensive 2026 corporate update detailing significant progress across its late-stage QTORIN platform, which leverages a proprietary topical rapamycin formulation for the treatment of rare dermatological and vascular conditions.
Kezar gains FDA lifeline for zetomipzomib amid strategic overhaul
Kezar Life Sciences (NASDAQ:KZR) announced Friday that the FDA has granted a formal Type C meeting for the first quarter of 2026, a move that could revive the clinical path for its lead asset, zetomipzomib, following months of regulatory uncertainty.
Appian vows to press trade secret claims in Pega "spy" case retrial
Appian Corp. (NASDAQ:APPN) announced it will pursue a second trial in its long-running trade secrets battle against Pegasystems (NASDAQ:PEGA0, following a Virginia Supreme Court ruling that refused to dismiss the case but sent it back to a lower court for a fresh look.




%20inhalation%20powder-640x640.png&w=1200&q=75)




-2-640x360.png&w=1200&q=75)
